Nurix Therapeutics Inc reports results for the quarter ended February 28 - Earnings Summary

Nurix Therapeutics

08/04/2025 21:14

Nurix Therapeutics Inc NRIX.OQ reported a quarterly adjusted loss of 67 cents​​ per share for the quarter ended February 28, higher than the same quarter last year, when the company reported EPS of -76 cents.  The mean expectation of seventeen analysts for the quarter was for a loss of 76 cents per share. Wall Street expected results to range from -96 cents to -50 cents per share.

Revenue rose 11.3% to $18.45 million from a year ago; analysts expected $12.71 million.

Nurix Therapeutics Inc's reported EPS for the quarter was a loss of 67 cents​.

The company reported a quarterly loss of $56.35 million.

Nurix Therapeutics Inc shares had fallen by 18.2% this quarter and lost 48.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 11.8% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Nurix Therapeutics Inc is $35.00

This summary was machine generated from LSEG data April 8 at 08:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Feb. 28 2025
-0.76
-0.67
Beat
Nov. 30 2024
-0.68
-0.75
Missed
Aug. 31 2024
-0.71
-0.67
Beat
May. 31 2024
-0.63
-0.71
Missed